Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 8:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 140 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Terminated No phase listed Observational

The Chimerix CMX001 Registry

NCT02167685
Conditions
Outcomes, Survival Rates
Interventions
CMX001
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
6 Months to 100 Years
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
47
States / cities
La Jolla, California • Los Angeles, California • Palo Alto, California + 30 more
Conditions
Extramammary Paget's Disease, Extramammary Paget Disease, Paget Disease, Extramammary, Extramammary Paget's Disease of Vulva (Diagnosis), Extramammary Paget's Disease of Vagina (Diagnosis), Extramammary Paget's Disease Vulva Invasive, Extramammary Paget's Disease of Anus (Diagnosis), Extramammary Paget's Disease of Anal Canal (Diagnosis), Extramammary Paget's Disease of Skin
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2050
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Non-Small-Cell Lung Cancer, Pleural Effusion, Malignant
Interventions
zoledronic acid
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
101
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Anaheim, California + 93 more
Conditions
Leishmaniasis
Interventions
Miltefosine
Drug
Lead sponsor
Knight Therapeutics (USA) Inc
Industry
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Poolesville, Maryland
Conditions
Obstructive Hypertrophic Cardiomyopathy
Interventions
Mavacamten, Non-mavacamten symptomatic oHCM therapy
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
60
States / cities
Anchorage, Alaska • Tucson, Arizona • Little Rock, Arkansas + 48 more
Conditions
Fractures, Bone
Interventions
NanoBone® Bone Graft
Device
Lead sponsor
Artoss Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Congenital Bleeding Disorder, Glanzmann's Disease
Interventions
activated recombinant human factor VII
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Not listed
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Princeton, New Jersey
Conditions
Fabry Disease
Interventions
migalastat HCl, ERT
Drug
Lead sponsor
Amicus Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
8
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Atlanta, Georgia + 5 more
Conditions
Lung Cancer, Bilateral Cancer, Lung Transplant
Interventions
Double Lung Transplantation
Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 75 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Euvolemic Hyponatremia, Hypervolemic Hyponatremia
Interventions
Not listed
Lead sponsor
Otsuka America Pharmaceutical
Industry
Eligibility
18 Years and older
Enrollment
5,028 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
72
States / cities
Azusa, California • Inglewood, California • Los Angeles, California + 58 more
Withdrawn No phase listed Observational Accepts healthy volunteers

PREHEVBRIO Pregnancy Outcomes Registry

NCT06097312
Conditions
Vaccine Exposure During Pregnancy
Interventions
Data collection
Other
Lead sponsor
VBI Vaccines Inc.
Industry
Eligibility
Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2032
U.S. locations
1
States / cities
Overland Park, Kansas
Conditions
Heart Failure NYHA Class III
Interventions
Cordella™ Heart Failure System
Device
Lead sponsor
Endotronix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
4
States / cities
Los Angeles, California • San Francisco, California • Lebanon, New Hampshire + 1 more
Conditions
Continuous Renal Replacement Therapy
Interventions
Continuous Renal Replacement Therapy
Procedure
Lead sponsor
AKI Critical Care Research Foundation
Other
Eligibility
18 Years to 89 Years
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Lupus Nephritis
Interventions
LUPKYNIS
Drug
Lead sponsor
Aurinia Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
South Gate, California
Conditions
Primary Headache Disorders
Interventions
Ausanil
Drug
Lead sponsor
VR1 Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Summit, New Jersey
Conditions
Heart Block Complete, Heart Block Second Degree
Interventions
Dexamethasone, No Dexamethasone
Drug · Other
Lead sponsor
The Hospital for Sick Children
Other
Eligibility
16 Years to 50 Years · Female only
Enrollment
350 participants
Timeline
2020 – 2029
U.S. locations
12
States / cities
Phoenix, Arizona • San Francisco, California • Denver, Colorado + 9 more
Conditions
Primary Invasive Breast Cancer
Interventions
Observational
Other
Lead sponsor
Myriad Genetic Laboratories, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
855 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
52
States / cities
Burbank, California • Roseville, California • Fort Myers, Florida + 40 more
Completed No phase listed Observational Results available

Philips Intracardiac Echocardiography (ICE) Clinical Registry

NCT04950192
Conditions
Atrial Fibrillation, Stroke, Valve Disease, Heart, Atrial Septal Defect, Patent Foramen Ovale, Mitral Valve Disease, Tricuspid Valve Disease, Aortic Valve Disease
Interventions
ICE Image guidance
Device
Lead sponsor
Philips Clinical & Medical Affairs Global
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
5
States / cities
Aurora, Colorado • Chicago, Illinois • Boston, Massachusetts + 2 more
Conditions
Uterine Fibroid, Arteriovenous Malformations, Hypervascular Tumors, Benign Prostatic Hyperplasia
Interventions
Treatment with HydroPearl via radial access
Device
Lead sponsor
Terumo Medical Corporation
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
6
States / cities
Los Angeles, California • Chicago, Illinois • St Louis, Missouri + 3 more
Conditions
Achondroplasia
Interventions
Not listed
Lead sponsor
Pfizer
Industry
Eligibility
0 Years to 15 Years
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
14
States / cities
Los Angeles, California • Torrance, California • Wilmington, Delaware + 7 more
Conditions
Polycythemia Vera, ET (Essential Thrombocythemia), Polycythemia Vera (PV), Essential Thrombocythemia (ET), Primary Myelofibrosis (MF), Primary Myelofibrosis (PMF), Myelofibrosis, Myelofibrosis (MF), Myelofibrosis, Primary, Myelofibrosis, Post ET, Myelofibrosis, Post PV, Myelofibrosis (PMF), Myelofibrosis,MF, Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis, Myelofibrosis Due to and Following Polycythemia Vera, Myelofibrosis Transformation in Essential Thrombocythemia, Myelofibrosis With High Molecular Risk Mutations, MF, Secondary Myelofibrosis, Secondary Myelofibrosis in Myeloproliferative Disease, Secondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis), Post-Polycythemia Vera Myelofibrosis, Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), Post-polycythemia Vera Myelofibrosis(Post-PV MF), Post-PV MF, Post-Essential Thrombocythemia Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis (PET-MF), Post-essential Thrombocythemia Myelofibrosis(Post-ET MF), Post-essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-ET MF, Pre-fibrotic Myelofibrosis, Myeloproliferative Disorder, Myeloproliferative Disorders, Myeloproliferative Disorders (MPD), Myeloproliferative Neoplasms (MPNs), Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis, Myeloproliferative Neoplasm With 10% Blasts or Higher, Myeloproliferative Neoplasms, MPN, MPN (Myeloproliferative Neoplasms), MPN-associated Myelofibrosis, Myeloproliferative Neoplasm, Unclassifiable, Myeloproliferative Neoplasm, Not Otherwise Specified, Accelerated Phase MPN, Accelerated Phase Myeloproliferative Neoplasm, Blast Phase MPN, Blast Phase Myeloproliferative Neoplasm, Thrombocythemia Myelofibrosis (PET-MF), Thrombocythemia, Essential, Thrombocythemia, Hemorrhagic, Agnogenic Myeloid Metaplasia, Chronic Idiopathic Myelofibrosis, Idiopathic Myelofibrosis, MDS/MPN Crossover Syndromes
Interventions
Not listed
Lead sponsor
MPN Research Foundation
Other
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Recruiting No phase listed Observational

Vitaccess Real MG Registry

NCT06064461
Conditions
Myasthenia Gravis
Interventions
Not listed
Lead sponsor
Vitaccess Ltd
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2034
U.S. locations
6
States / cities
Orange, California • O'Fallon, Illinois • Lexington, Kentucky + 3 more
Conditions
Degenerative Disc Disease, Herniated Disc, Spinal Stenosis, Spondylolithesis, Spinal Deformity, Cervical Myelopathy, Failed Back Surgery Syndrome, Spinal Cord Neoplasms
Interventions
Bone graft substitute, autograft or allograft
Device
Lead sponsor
Baxter Healthcare Corporation
Industry
Eligibility
18 Years and older
Enrollment
329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
12
States / cities
San Francisco, California • Atlanta, Georgia • Carrollton, Georgia + 9 more
Not listed No phase listed Observational

MIMICS-3D-USA Registry Study

NCT04640597
Conditions
Peripheral Arterial Disease
Interventions
BioMimics 3D Vascular Stent System
Device
Lead sponsor
Veryan Medical Ltd.
Industry
Eligibility
18 Years to 85 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
27
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Darien, Connecticut + 20 more